Sign In
Buy CMND
$2.91
-0.0100 (-0.342%)
At Close: Jun 03, 2026
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
09:10am, Wednesday, 31'st Dec 2025
Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery a
Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery a
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery a
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery a
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
06:32am, Friday, 12'th Dec 2025
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery a
Why Did Clearmind Medicine Shares Plunge 29% After Hours?
03:28am, Thursday, 11'th Dec 2025
Clearmind Medicine shares dropped in after-hours trading following the company's announcement of a 1-for-40 reverse stock split.
Clearmind Medicine Announces 1-for-40 Reverse Share Split
04:15pm, Wednesday, 10'th Dec 2025
Vancouver, Canada, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and d
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
05:00pm, Friday, 05'th Dec 2025
Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and d
Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and d
Vancouver, Canada, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and d
Why Did Clearmind Medicine Shares Jump 7% In Pre-Market Trading?
04:32am, Wednesday, 26'th Nov 2025
Clearmind Medicine rose 7.09% in pre-market trading after announcing enrollment of first patient in trial for alcohol use disorder.
First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100 Vancouver, Canada, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: C
Vancouver, Canada, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and d
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
06:01am, Thursday, 20'th Nov 2025
Prestigious Hadassah Medical Center Joins Yale, Johns Hopkins, Tel Aviv Sourasky and IMCA, in Evaluating the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate
November 19, 2025 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera” or the “ Company”), a clinical-stage biotech company and an wholly-
